Testosterone nasal gel (Natesto) for hypogonadism.
Level 5 - mechanism / opinion, no new human data
Narrative drug review without primary experimental data or systematic search methodology
What was done
This article is a drug evaluation summarizing available evidence on Natesto, an intranasal testosterone gel administered three times daily for the treatment of hypogonadism.
What was found
The abstract reports that Natesto normalized low serum testosterone levels in patients with hypogonadism in a single study. No numerical data, sample sizes, or statistical results are provided in the abstract.
Why it matters
Natesto provides an alternative intranasal delivery method for testosterone replacement, though its patient acceptability relative to established transdermal and intramuscular options remains unproven.
Limits
The abstract describes only a single study and omits sample size, patient characteristics, and quantitative outcomes. Comparative acceptability is unstudied, and safety concerns remain regarding use in age-related hypogonadism.
Cited by
- supports Natesto is an FDA-approved intranasal testosterone spray for testosterone replacement therapy in men.